RPRX
Royalty Pharma plc
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+18/100
Last price
56.44
▼ 0.22 (0.39%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
56.17
Prev close
56.66
Day high
57.13
Day low
56.04
Volume
2.43M
Market cap
$32.61B
P/E (TTM)
30.02
52W range
35.23 – 64.38
Day trading desk
Gap from prior close
-0.86%
Prior close 56.66
VWAP
56.53
-0.17% from price
Relative volume
0.67×
Normal
Session range
2.79%
55.60 – 57.15
Position in range
54%
Mid range
ATR (14D)
1.08
1.91% of price
Prior day high
57.25
PDH
Prior day low
56.01
PDL
Bid / ask spread
—
Quote not published
Session volume
1.98M
Avg 2.93M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.06%
-5.0%
1M
-11.76%
-12.9%
3M
-3.31%
-7.8%
6M
+20.42%
+2.2%
YTD
+46.07%
+31.8%
1Y
+56.47%
+40.1%
3Y
+107.96%
+25.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on RPRX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-286.55K
Net selling
Buy transactions
19
360.51K shares
Sell transactions
14
647.05K shares
Net transactions
+33
Buys less sells
Sell : buy shares
1.8 : 1
Mixed
Insider-held shares
28.89M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 5, 26 | URIST MARSHALL J. Officer |
SELL | 4.13K | $235.59K | Direct |
| Sep 30, 26 | BASSLER BONNIE L Director |
STOCK | 642 | $37.50K | Direct |
| Sep 28, 26 | URIST MARSHALL J. Officer |
SELL | 4.13K | $238.81K | Direct |
| Sep 22, 26 | HITE CHRISTOPHER Officer |
SELL | 100.00K | $5.85M | Indirect |
| Aug 19, 26 | HITE CHRISTOPHER Officer |
STOCK | 16.80K | $0 | Direct |
| Aug 18, 26 | HITE CHRISTOPHER Officer |
SELL | 100.00K | $6.00M | Indirect |
| Aug 13, 26 | COYNE TERRANCE P Chief Financial Officer |
SELL | 11.00K | $645.55K | Indirect |
| Aug 5, 26 | HITE CHRISTOPHER Officer |
STOCK | 11.00K | $0 | Indirect |
| Aug 5, 26 | COYNE TERRANCE P Chief Financial Officer |
STOCK | 11.00K | $0 | Indirect |
| Aug 5, 26 | URIST MARSHALL J. Officer |
STOCK | 8.25K | $0 | Direct |
| Aug 5, 26 | LEGORRETA PABLO G Chief Executive Officer |
STOCK | 65.22K | $0 | Direct |
| Jul 1, 26 | URIST MARSHALL J. Officer |
SELL | 9.10K | $508.45K | Direct |
| Jun 30, 26 | HITE CHRISTOPHER Officer |
SELL | 130.00K | $7.35M | |
| Jun 30, 26 | BASSLER BONNIE L Director |
STOCK | 689 | $37.48K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BASSLER BONNIE L |
Director | 79.82K | Stock Award(Grant) |
COYNE TERRANCE P |
Chief Financial Officer | — | Sale |
DESOUZA ERROL B |
Director | 81.35K | Stock Award(Grant) |
ENGELBERT CATHERINE M. |
Director | 55.67K | Stock Award(Grant) |
FERNANDEZ HENRY A |
Director | 123.52K | Stock Award(Grant) |
HITE CHRISTOPHER |
Officer | — | Sale |
LEGORRETA PABLO G |
Chief Executive Officer | 4.91M | Stock Award(Grant) |
LLOYD GEORGE W |
Officer | — | Sale |
LOVE TED WENDELL |
Director | 58.39K | Stock Award(Grant) |
NORDEN GREGORY |
Director | 196.35K | Stock Award(Grant) |
Fundamentals
Market cap$32.61B
Enterprise value$36.21B
Revenue (TTM)$2.54B
Gross profit$2.43B
EBITDA$1.56B
Net income$811.99M
EPS (TTM)$1.88
Free cash flow$-1.20B
Total cash$836.99M
Total debt$8.96B
Book value / share$15.33
Shares outstanding445.28M
Float417.57M
Short % of float2.65%
Dividend yield1.66%
Beta (5Y)0.41
Valuation & profitability ratios
Trailing P/E30.02
Forward P/E9.84
PEG ratio1.32
Price / sales—
Price / book3.68
EV / revenue14.28
EV / EBITDA23.25
Gross margin95.82%
Operating margin19.75%
Profit margin32.02%
Return on equity13.96%
Return on assets5.09%
Debt / equity91.58
Current ratio2.80
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.38B | $2.26B | $2.35B | $2.24B | +5.1% |
| Operating revenue | $2.38B | $2.26B | $2.35B | $2.24B | +5.1% |
| Research & development | $452.00M | $2.00M | $52.00M | $177.11M | +22,500.0% |
| Selling, general & admin | $573.48M | $236.67M | $249.75M | $227.30M | +142.3% |
| Total operating expense | $818.67M | $971.13M | $862.40M | $1.31B | -15.7% |
| Operating income | $1.56B | $1.29B | $1.49B | $922.89M | +20.7% |
| Net interest income | -$274.07M | -$178.17M | -$114.90M | -$109.63M | -53.8% |
| Pre-tax income | $1.32B | $1.33B | $1.70B | $230.06M | -0.5% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | $770.95M | $858.98M | $1.13B | $42.83M | -10.2% |
| Net income to common | $770.95M | $858.98M | $1.13B | $42.83M | -10.2% |
| Basic EPS | 1.80 | 1.93 | 2.54 | 0.10 | -6.6% |
| Diluted EPS | 1.37 | 1.45 | 2.53 | 0.10 | -5.5% |
| EBIT | $1.63B | $1.56B | $1.89B | $418.02M | +4.9% |
| EBITDA | $1.64B | $1.56B | $1.89B | $423.69M | +5.1% |
| Basic shares | 428.67M | 445.99M | 447.60M | 437.96M | -3.9% |
| Diluted shares | 564.00M | 594.00M | 602.90M | 437.97M | -5.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $618.70M | $929.03M | $477.01M | $1.71B | — | -33.4% |
| Cash & short-term investments | $1.49B | $1.77B | $1.23B | $2.43B | — | -15.8% |
| Total current assets | $1.53B | $1.80B | $1.27B | $2.55B | — | -15.2% |
| Goodwill & intangibles | $924.63M | $0 | — | $0 | $5.67M | — |
| Total assets | $19.62B | $18.22B | $16.38B | $16.81B | — | +7.7% |
| Total current liabilities | $636.21M | $1.25B | $161.38M | $1.17B | — | -49.2% |
| Current debt | $380.00M | $997.77M | — | $997.51M | — | -61.9% |
| Long-term debt | $8.57B | $6.61B | $6.14B | $6.12B | — | +29.6% |
| Total debt | $8.95B | $7.61B | $6.14B | $7.12B | — | +17.6% |
| Total liabilities | $9.91B | $7.88B | $6.30B | $7.29B | — | +25.7% |
| Retained earnings | $2.36B | $2.85B | $2.52B | $1.96B | — | -17.2% |
| Shareholder equity | $6.48B | $6.95B | $6.53B | $5.63B | — | -6.8% |
| Working capital | $891.88M | $548.52M | $1.11B | $1.39B | — | +62.6% |
| Net tangible assets | $5.55B | $6.95B | $6.53B | $5.63B | — | -20.1% |
| Shares issued | 428.67M | 445.99M | 446.69M | 443.17M | — | -3.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $1.32B | $1.33B | $1.70B | $230.06M | -0.5% |
| Depreciation & amortisation | $3.85M | $0 | $0 | $5.67M | — |
| Stock-based compensation | $289.89M | $2.34M | $2.36M | $2.17M | +12,267.5% |
| Change in working capital | -$17.15M | $53.38M | $5.38M | $32.66M | -132.1% |
| Operating cash flow | $2.49B | $2.77B | $2.99B | $2.14B | -10.1% |
| Investing cash flow | -$1.61B | -$2.68B | -$2.07B | -$1.03B | +39.7% |
| Share buybacks | -$1.23B | -$229.65M | -$304.76M | $0 | -434.5% |
| Dividends paid | -$378.25M | -$376.46M | -$358.33M | -$333.32M | -0.5% |
| Financing cash flow | -$1.19B | $361.14M | -$2.15B | -$944.86M | -428.4% |
| Free cash flow | $2.49B | $2.77B | $2.99B | $2.14B | -10.1% |
| End cash position | $618.70M | $929.03M | $477.01M | $1.71B | -33.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $674.14M | $630.58M | $621.99M | $609.29M | $578.66M | +6.9% |
| Operating revenue | $674.14M | $630.58M | $621.99M | $609.29M | $578.66M | +6.9% |
| Research & development | $97.85M | $39.79M | $50.50M | $50.50M | $300.50M | +145.9% |
| Selling, general & admin | $161.89M | $159.49M | $164.27M | $118.73M | $179.77M | +1.5% |
| Total operating expense | $541.02M | -$1.91M | $233.61M | $182.13M | $368.87M | +28,500.1% |
| Operating income | $133.12M | $632.48M | $388.38M | $427.16M | $209.80M | -79.0% |
| Net interest income | -$88.49M | -$87.49M | -$87.10M | -$72.66M | -$60.34M | -1.1% |
| Pre-tax income | $81.49M | $468.26M | $355.91M | $444.21M | $92.64M | -82.6% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — |
| Net income | $17.88M | $294.69M | $214.21M | $288.22M | $32.18M | -93.9% |
| Net income to common | $17.88M | $294.69M | $214.21M | $288.22M | $32.18M | -93.9% |
| Basic EPS | 0.04 | 0.66 | 0.50 | 0.67 | 0.07 | -93.9% |
| Diluted EPS | 0.03 | 0.53 | 0.38 | 0.51 | 0.05 | -93.9% |
| EBIT | $175.10M | $561.98M | $450.08M | $523.77M | $161.30M | -68.8% |
| EBITDA | $176.40M | $563.15M | $451.28M | $525.05M | $162.68M | -68.7% |
| Basic shares | 445.75M | 443.63M | 428.67M | 429.03M | 432.29M | +0.5% |
| Diluted shares | 557.00M | 557.00M | 556.00M | 560.00M | 562.00M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $811.99M | $586.39M | $618.70M | $938.94M | $631.91M | +38.5% |
| Cash & short-term investments | $1.73B | $1.39B | $1.49B | $1.82B | $1.49B | +24.4% |
| Total current assets | $1.76B | $1.43B | $1.53B | $1.85B | $1.52B | +23.8% |
| Goodwill & intangibles | $923.53M | $924.63M | $924.63M | $924.63M | $924.63M | -0.1% |
| Total assets | $19.82B | $19.82B | $19.62B | $19.35B | $18.32B | +0.0% |
| Total current liabilities | $630.93M | $535.68M | $636.21M | $530.80M | $1.21B | +17.8% |
| Current debt | $380.00M | $380.00M | $380.00M | $380.00M | $999.44M | 0.0% |
| Long-term debt | $8.58B | $8.58B | $8.57B | $8.57B | $7.00B | +0.1% |
| Total debt | $8.96B | $8.96B | $8.95B | $8.95B | $8.00B | +0.1% |
| Total liabilities | $10.03B | $9.88B | $9.91B | $9.73B | $8.82B | +1.6% |
| Retained earnings | $2.46B | $2.51B | $2.36B | $2.30B | $2.22B | -1.9% |
| Shareholder equity | $6.83B | $6.89B | $6.48B | $6.41B | $6.35B | -0.8% |
| Working capital | $1.13B | $890.13M | $891.88M | $1.32B | $313.71M | +27.4% |
| Net tangible assets | $5.91B | $5.96B | $5.55B | $5.49B | $5.42B | -0.9% |
| Shares issued | 445.75M | 443.63M | 428.67M | 429.03M | 432.29M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $81.48M | $468.26M | $355.91M | $441.21M | $92.64M | -82.6% |
| Depreciation & amortisation | $1.29M | $1.17M | $1.20M | $1.28M | $1.38M | +10.5% |
| Stock-based compensation | $107.07M | $121.99M | $125.77M | $72.84M | $90.77M | -12.2% |
| Change in working capital | $86.69M | -$80.42M | $48.51M | -$50.88M | $49.69M | +207.8% |
| Operating cash flow | $728.46M | $718.23M | $827.15M | $702.62M | $363.98M | +1.4% |
| Investing cash flow | -$229.72M | -$477.87M | -$847.80M | -$958.31M | -$311.98M | +51.9% |
| Share buybacks | -$44.64M | -$50.10M | -$80.54M | -$146.49M | -$291.57M | +10.9% |
| Dividends paid | -$104.92M | -$104.49M | -$94.34M | -$95.31M | -$93.24M | -0.4% |
| Financing cash flow | -$273.15M | -$272.67M | -$299.60M | $562.74M | -$507.81M | -0.2% |
| Free cash flow | $728.46M | $718.23M | $827.15M | $702.62M | $363.98M | +1.4% |
| End cash position | $811.99M | $586.39M | $618.70M | $938.94M | $631.91M | +38.5% |
Options analytics
Put / call volume
0.90
Call-heavy session
Put / call open interest
0.33
Positioning, not flow
Max pain
40.00
-29.1% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
39
Contracts, this expiry
Put volume
35
Contracts, this expiry
Heaviest call OI
47.50
5 contracts
Heaviest put OI
35.00
1 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.27 | 1.32 | +3.9% |
| Mar 2026 | 1.18 | 1.30 | +9.4% |
| Dec 2025 | 1.33 | 1.47 | +10.0% |
| Sep 2025 | 1.04 | 1.17 | +12.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.18 | 6 | $884.84M | +8.7% |
| Next quarter | 1.55 | 5 | $941.32M | +7.7% |
| Current year | 5.34 | 6 | $3.50B | +7.7% |
| Next year | 5.73 | 6 | $3.81B | +8.7% |
Analyst targets & ownership
Mean target$65.13
High target$70.00
Low target$61.00
Implied upside15.39%
Analyst count8
ConsensusSTRONG BUY
Strong buy / Buy2 / 5
Hold1
Sell / Strong sell0 / 0
Held by insiders6.49%
Held by institutions87.68%
Institutions holding997
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
57.70
-2.18% from price
SMA 20
58.26
-3.13% from price
SMA 50
59.33
-4.87% from price
SMA 100
57.46
-1.78% from price
SMA 200
51.26
+10.10% from price
EMA 12
57.77
-2.30% from price
EMA 26
58.54
-3.58% from price
EMA 50
58.52
-3.56% from price
RSI (14)
33.2
Neutral
MACD (12,26,9)
-0.77
Hist -0.22
ATR (14)
1.08
1.91% of price
Realised vol 30D
21.9%
Annualised
Bollinger upper
59.99
20, 2σ
Bollinger lower
56.53
20, 2σ
50 / 200 cross
Golden
59.33 vs 51.26
Trend bias
Above 200
+10.10%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.25
Less volatile than market
Correlation to SPY
0.14
Largely independent
Realised vol 30D
21.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-11.8%
Peak to trough
Max drawdown 5Y
-45.6%
Peak to trough
ATR 14
1.08
1.91% of price
Beta (reported)
0.41
5Y monthly, from filing
Short interest
Shares short
11.65M
Prior 11.61M
Change vs prior
+0.4%
Shorts adding
% of float
2.65%
Normal
% of shares out
2.62%
Against total outstanding
Days to cover
3.9
Liquid
Float
417.57M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 8, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 7, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jul 13, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| May 7, 26 | Citigroup | MAINTAINED | Buy | Buy |
| May 7, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Apr 21, 26 | UBS | MAINTAINED | Buy | Buy |
| Apr 10, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Jan 30, 26 | UBS | UPGRADE | Neutral | Buy |
| Jan 27, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Dec 11, 25 | TD Cowen | MAINTAINED | Buy | Buy |
| Oct 10, 25 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Sep 30, 25 | Goldman Sachs | INITIATED | — | Buy |
Dividends & splits
Forward rate$0.94 / yr
Forward yield1.66%
5-year avg yield2.17%
Payout ratio48.40%
Ex-dividend dateAug 14, 2026
Next pay dateSep 10, 2026
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-06-04
Corporate Changes & Voting Matters
8-K · 2026-05-28
Corporate Changes & Voting Matters
8-K · 2026-05-06
Corporate Changes & Voting Matters
8-K · 2026-04-13
Annual Report to Shareholders
ARS · 2026-04-10
Periodic Financial Reports
10-K · 2026-02-11
Corporate Changes & Voting Matters
8-K · 2025-12-22
Headlines
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
Motley Fool · 6d ago
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
MarketBeat · 12d ago
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Motley Fool · 12d ago
Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run
Simply Wall St. · 14d ago
Royalty Pharma (RPRX) Could Be 10% Undervalued As Conference Spotlight Returns
Simply Wall St. · 14d ago
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
GlobeNewswire · 21d ago
Blood Cancer United Announces $7.5 Million Gift From Royalty Pharma to Expand Therapy Acceleration Program
PR Newswire · 21d ago
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?
Insider Monkey · 27d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.